“Buprenorphine medication-assisted treatment adherence was associated with higher dose, older age and previous history of psychosocial therapy, according to data presented at the U.S. Psychiatric and Mental Health Congress.
To determine factors associated with adherence to buprenorphine medication-assisted treatment in the first year following treatment initiation, researchers conducted a retrospective cohort study of administrative medical and pharmacy claims for commercial (n = 16,085) and Medicaid (n = 5,688) claims for individuals with a diagnosis of opioid use disorder initiating buprenorphine medication-assisted treatment. Buprenorphine medication-assisted treatment was measured over 12 months after initiation, using proportion of days covered. Participants with a proportion of days covered of 0.8 or greater were considered adherent. Participants had a mean age of approximately 32 years.
Overall, 37.1% of commercial participants and 41.3% of Medicaid participants were adherent to buprenorphine medication-assisted treatment.
Increased odds for adherence were associated with receiving a higher average daily dose (24 mg or greater) of buprenorphine, older age, living in a rural area, living in the Northeast, use of other medication-assisted treatment prior to buprenorphine initiation, and receiving psychosocial therapy prior to buprenorphine initiation among commercial participants.
Source: Healio.com – October 26, 2016